Psoriasis Affects 2–3% of Adults, and Vitamin D Is Already Part of Its Treatment

Psoriasis affects roughly 125 million people worldwide — about 2–3% of the global adult population. It is an immune-mediated inflammatory skin disease, not simply a cosmetic problem, and dermatologists have been prescribing topical vitamin D analogues (calcipotriol, calcitriol) as a first-line option for decades. What is less discussed is the growing body of evidence that systemic vitamin D status — measured as 25-hydroxyvitamin D (25(OH)D) in the blood — is also consistently lower in people with psoriasis, and that this gap may influence disease severity. Understanding why that connection exists, and what the trial data actually says, matters if you have psoriasis or are tracking your sun exposure and vitamin D levels.

Why Vitamin D and Psoriasis Are Biologically Connected

Psoriasis is driven by an overactive immune response, specifically an excess of T-helper 17 (Th17) cells and the cytokines IL-17 and IL-23. Vitamin D's active form, 1,25-dihydroxyvitamin D (calcitriol), directly modulates T-cell function. It pushes the immune response away from Th17 and Th1 activity and toward the anti-inflammatory Th2 and T-regulatory phenotypes. This immunomodulatory mechanism is documented in human immune cell studies and is precisely why topical D analogues work at the lesion site.

Vitamin D also slows keratinocyte (skin cell) proliferation. In psoriasis, keratinocytes divide too fast, producing the characteristic thickened plaques. Calcipotriol binds to vitamin D receptors (VDR) in skin cells and normalizes their cycle. A 2020 review in Frontiers in Immunology summarised both the keratinocyte and immune mechanisms, noting that VDR expression is altered in psoriatic skin compared with healthy controls — a finding that may partly explain why topical treatment doesn't always translate into large effects from oral supplementation alone.

What Blood-Level Studies Actually Find

Multiple cross-sectional studies consistently report lower 25(OH)D levels in people with psoriasis compared with matched controls. A 2013 meta-analysis published in British Journal of Dermatology pooled data from 21 studies and found a statistically significant association between low vitamin D status and psoriasis presence and severity. Importantly, several studies within the pool found that the Psoriasis Area and Severity Index (PASI) score — the standard clinical severity metric — correlated inversely with 25(OH)D levels: higher severity, lower D.

A subsequent case-control study in Dermato-Endocrinology found that 79% of psoriasis patients had 25(OH)D below 30 ng/mL (insufficient or deficient), versus 47% of healthy controls. That gap is clinically meaningful and not easily explained by sun avoidance alone, since many participants had similar self-reported outdoor habits.

These observational findings don't prove causation. Chronic inflammation itself may suppress vitamin D metabolism — a reverse-causality concern that applies to many inflammatory conditions. But the biological plausibility and the clinical success of topical D analogues together make the relationship more than coincidental.

Topical vs. Oral: How the Evidence Differs

Topical Vitamin D Analogues: Strong Trial Evidence

Topical calcipotriol (also spelled calcipotriene) has randomized controlled trial (RCT) support going back to the early 1990s. A Cochrane review of treatments for chronic plaque psoriasis, updated in Cochrane Database of Systematic Reviews (2016), placed vitamin D analogues as among the most effective non-steroidal topical options, with good tolerability for mild-to-moderate plaque psoriasis. The combination of calcipotriol with a topical corticosteroid (betamethasone dipropionate) performs better than either alone and is now a standard of care in many dermatology guidelines.

Oral Supplementation: Promising but Smaller Effects

The evidence for oral vitamin D3 supplementation on systemic psoriasis control is more mixed. A randomized trial published in Journal of Dermatological Treatment found that 35,000 IU/week of oral vitamin D3 over six months significantly reduced PASI scores in patients who began the trial deficient (below 20 ng/mL). The reduction was clinically meaningful in that trial, but the dose was high and not a typical supplement protocol.

At more typical supplementation levels (1,000–4,000 IU/day), the systemic evidence is weaker. Some researchers argue the dose required to shift immune parameters is higher than what most adults take. This does not mean supplementation is ineffective for vitamin D status correction — it almost certainly helps if someone is deficient — but it means oral vitamin D3 should not be expected to replace topical treatment or phototherapy for the skin lesions themselves.

Sunlight, UV Phototherapy, and Psoriasis

Sun exposure has been used to treat psoriasis for centuries, and modern narrowband UVB phototherapy is a first-line treatment for moderate-to-severe plaque psoriasis. Narrowband UVB targets the 311–313 nm wavelength range, which is also the core of vitamin D synthesis in skin — though vitamin D production is only one of several mechanisms at work in phototherapy. UVB also suppresses skin T-cell activity directly, independent of vitamin D.

A review of phototherapy mechanisms in Photodermatology, Photoimmunology & Photomedicine concluded that vitamin D synthesis is likely a contributing — but not the sole — mechanism behind UVB's benefits in psoriasis. Natural sunlight achieves a similar effect when UV index and exposure time are sufficient, which is part of why psoriasis often improves for patients who spend time in sunny climates.

For practical sun exposure, what matters is UVB — and UVB only reaches skin when the UV index is 3 or higher and the sun is roughly 35° or more above the horizon. Glass blocks UVB almost entirely, so indoor light provides no benefit for either vitamin D synthesis or psoriasis. If you're not sure when your local UV window opens, the vitamin D sun calculator at Rays uses your location and skin type to identify exactly when meaningful UVB is available.

The Psoriasis-Comorbidity Picture and Why D Status Matters Systemically

People with psoriasis face elevated risk of metabolic syndrome, cardiovascular disease, and type 2 diabetes — conditions where low vitamin D also appears consistently as a covarying factor. A large cohort analysis in JAMA Dermatology found that psoriasis severity correlates with cardiometabolic risk in a dose-dependent pattern: more severe skin disease, higher cardiovascular risk. Whether correcting vitamin D status helps on the cardiometabolic side in psoriasis patients specifically hasn't been tested in large RCTs, but the inflammatory overlap makes it a reasonable area to monitor.

Psoriatic arthritis (PsA), which develops in up to 30% of people with plaque psoriasis, also shows the low-D pattern. A study in Rheumatology found that PsA patients had significantly lower 25(OH)D levels than matched controls, and that lower levels correlated with disease activity scores. Given that vitamin D's VDR is expressed in joint tissue as well as skin, the mechanism connecting D status to joint inflammation is plausible, though RCT data in PsA is still limited.

Practical Implications: What People With Psoriasis Should Know

Testing Is the Starting Point

Given the high prevalence of low vitamin D in psoriasis populations (approaching 80% in some studies), testing 25(OH)D levels at least twice a year makes practical sense — once at the end of summer to capture peak levels and once at the end of winter when levels are typically lowest. The standard test is 25(OH)D, not 1,25-dihydroxyvitamin D, which is the active hormone form. The 25(OH)D test reflects your actual stored status. The Rays guide to vitamin D testing — when to test and what numbers mean covers the specifics of what lab results actually indicate.

Target Blood Levels and Supplement Considerations

For most adults, levels below 20 ng/mL (50 nmol/L) are considered deficient; 20–29 ng/mL is insufficient; 30–60 ng/mL covers the sufficient range. The mechanistic data — particularly immune modulation studies — suggest that levels toward the higher end of the sufficient range (40–60 ng/mL) may be more relevant for inflammatory conditions, though clinical trials targeting these specific bands in psoriasis haven't been completed at scale. Correcting frank deficiency is the unambiguous first step.

If supplementing, D3 (cholecalciferol) is preferred over D2 (ergocalciferol) because it raises 25(OH)D more reliably. Taking D3 with K2 (MK-7 form) is reasonable when supplementing longer-term to support proper calcium routing — particularly relevant if someone is correcting a large deficit with higher daily doses. For people starting with levels below 20 ng/mL, typical repletion doses of 2,000–4,000 IU/day are commonly used, with retesting at 8–12 weeks. The article on vitamin D dosage — how much D3 you actually need covers dosing evidence in more detail.

Sun Exposure: Real Benefit, Real Limits

Moderate sun exposure on clear skin raises both 25(OH)D and can directly improve plaques through UVB's local immunosuppressive effect. This is not a reason to abandon sun protection entirely — UV damage accumulates, and people with psoriasis who use biologics or immunosuppressants may have additional skin cancer considerations that their dermatologist should address individually. But for people with mild-to-moderate psoriasis who are not on immunosuppressants, strategic sun exposure during the UV window (UV index 3 or higher, mid-morning to mid-afternoon at mid-latitudes) is consistent with both vitamin D optimization and clinical dermatology practice.

How much exposure is 'enough' varies sharply by skin tone, season, and latitude. Someone with a Fitzpatrick type I skin tone at high summer UV index needs far less time than someone with type V or VI skin. The Rays article on how skin tone affects vitamin D synthesis and sun needs explains the melanin-UVB interaction in detail. Darker skin requires roughly 3–5 times more exposure for the same vitamin D output, and this same population already has higher background rates of vitamin D deficiency.

Winter and Latitude: When Sun Stops Working

At latitudes above roughly 35°N (covering most of the continental US north of Los Angeles, all of Canada, the UK, and most of Europe), winter UVB falls to near-zero for weeks or months. In this period, no amount of outdoor time will raise vitamin D through skin synthesis. People with psoriasis living at these latitudes face a compounding challenge: the season with the least sun is often also the season when cold, covered skin means less surface area exposed even on sunny days. Supplementation becomes the primary lever for maintaining levels, and a consistent daily protocol through the winter months is important. The Rays guide on vitamin D in winter and when supplements beat the sun covers the seasonal switch-over by latitude.

What Remains Uncertain

The association between systemic vitamin D status and psoriasis severity is real and replicated across populations, but whether correcting vitamin D deficiency through supplementation alone meaningfully reduces PASI scores in people who are not severely deficient is still an open question. The trials showing benefit have largely recruited patients who were clearly deficient at baseline, and the doses used (often well above typical supplement doses) make it hard to generalise to standard 2,000 IU/day protocols. Large RCTs targeting 25(OH)D normalization specifically in psoriasis patients — with PASI as the primary endpoint — are still needed.

The question of whether optimal vitamin D status (above 40 ng/mL) provides additional benefit beyond correcting deficiency is also contested. The evidence for effects at levels above 40 ng/mL in any condition, including psoriasis, remains preliminary. Maintaining levels in the sufficient 30–60 ng/mL range is a reasonable and evidence-consistent target; chasing higher numbers through supplementation introduces toxicity risk at the extreme end without clear added benefit.

Key Takeaways

Vitamin D is already embedded in psoriasis treatment through topical D analogues — this is not an alternative-medicine claim but standard dermatology practice. Systemic vitamin D status (25(OH)D) is consistently lower in people with psoriasis than in matched controls, and lower levels correlate with higher PASI severity scores in cross-sectional data. UVB exposure — whether from targeted phototherapy or natural sunlight during the active UV window — helps psoriasis through multiple mechanisms, of which vitamin D synthesis is one. Oral vitamin D3 supplementation can correct deficiency and is a reasonable adjunct, particularly in winter or at high latitudes, but should not replace dermatologist-directed treatment. Testing 25(OH)D twice a year gives a clear picture of where your levels actually sit across seasons. People with psoriatic arthritis face additional reason to monitor levels given the inflammatory overlap. The comorbidity profile of psoriasis — cardiovascular, metabolic, joint — overlaps substantially with conditions where vitamin D insufficiency also appears consistently, making systemic D status worth tracking even beyond skin outcomes.

What to do next

If psoriasis is part of your health picture, knowing your 25(OH)D level is the first practical step — and knowing whether your daily outdoor time is actually generating UVB is the second. Use the vitamin D sun calculator to check whether your current location and season allow meaningful synthesis today. For ongoing tracking without having to manually log sessions, Rays automatically detects your outdoor time and UV exposure so you can see whether your sun window is open — and when to lean on supplements instead.